Medicina nuclear

2023

1. Abdominal Castleman's disease with 18F-FDG PET-CT

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 6, pp. 418-419

2. Artificial Intelligence Increases the Agreement among Physicians Classifying Focal Skeleton/Bone Marrow Uptake in Hodgkin’s Lymphoma Patients Staged with [18F]FDG PET/CT—a Retrospective Study

   Nuclear Medicine and Molecular Imaging, Vol. 57, Núm. 2, pp. 110-116

3. Description of a different quantification method for amyloid burden (burdenDPD) and validation of SPECT/CT in cardiac amyloidosis

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 171-177

4. Effectiveness of 11C-choline PET/CT in prostate cancer surveillance

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 2, pp. 93-99

5. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

   European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

6. Nuclear Cardiology in the COVID-19 pandemic

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 2, pp. 106-112

7. Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 156-162

8. Update on iodine-refractory differentiated thyroid carcinoma

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 5, pp. 324-333

9. Use of 125I seeds in the surgical management of a complex oncological case

   Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 2, pp. 116-118